Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson’s and ALS

Biotech TV

Watch more

A British mitochondrial startup wants to break ground in ALS and Parkinson’s....NRG raises $67 million for a small molecule for Parkinson’s and ALS